Bioversys (BIOV.SW)

Bioversys stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · SIX Swiss Exchange · Switzerland

CHF 23.60▼ -3.67%

Prices as of Oct 27, 2026 · CHF

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

48%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Bioversys in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Bioversys

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Bioversys a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between CHF 21.35 and CHF 25.75; in 9 out of 10, between CHF 18.08 and CHF 30.41. Estimated annual volatility is 55%.

Price, last 12 months (weekly close)

Key numbers

Market cap: CHF 152M
Market cap (USD): $183M
52-week high: CHF 30.70
52-week low: CHF 21.20
Revenue (12 months): CHF 4.6M
Net margin: 0.0%

What this means

ATLAS does not publish a fair value for BIOV.SW right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks BIOV.SW has traded between CHF 21.20 and CHF 30.70. Today it is 23.1% below that high and 11% above its low.

About the company

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections.

Want to see everything about Bioversys?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Bioversys do?

What is the chance BIOV.SW goes up next month?

48%: close to a coin flip. In half of the simulated outcomes, BIOV.SW ends the month between CHF 21.35 and CHF 25.75.

How big is Bioversys and what is its P/E ratio?

Bioversys's market capitalization is CHF 152M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is BIOV.SW?

ATLAS estimates annual volatility at 55%. In a typical month, half of the outcomes end between CHF 21.35 and CHF 25.75.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer